VASTox Signs Two Deals Totaling $1.3M for High-Content Zebrafish Screening, Chemistry | GenomeWeb
VASTox, a chemical genomics firm based in Oxford, UK, said this week that it had signed two drug-discovery collaborations worth a total of €1 million ($1.3 million) over the next 12 months.
 
One agreement, with Italian pharmaceutical company Rottapharm, is worth €365,000 and is centered around VASTox’s core technology platform, which is based on high-throughput small-molecule screening in zebrafish and fruit flies.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.